Recursion Pharma Files 8-K for Reg FD Disclosure

Ticker: RXRX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1601830

Recursion Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRecursion Pharmaceuticals, Inc. (RXRX)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, corporate-filing, disclosure

TL;DR

**RXRX just dropped an 8-K for Reg FD; check the exhibits for the real news.**

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This filing, under SEC File Number 001-40323, indicates that the company is making certain information public, likely related to an event on January 8, 2024. For investors, this matters because Regulation FD disclosures often contain material non-public information that could impact the stock price, making it crucial to review the accompanying exhibits for specific details.

Why It Matters

This filing signals that Recursion Pharmaceuticals is making important information public, which could influence investor sentiment and the stock's performance. Investors should examine the exhibits for specific details that could affect the company's valuation.

Risk Assessment

Risk Level: medium — The risk is medium because Regulation FD disclosures can contain significant news, but without the exhibits, the exact impact is unknown.

Analyst Insight

A smart investor would immediately seek out the exhibits referenced in this 8-K to understand the specific nature of the Regulation FD disclosure, as this information could be material and impact the stock price.

Key Numbers

  • 001-40323 — SEC File Number (identifies Recursion Pharmaceuticals, Inc.'s registration with the SEC)
  • 2024-01-08 — Date of Report (indicates when the earliest event reported in the 8-K occurred)
  • $0.00001 — par value per share (par value of Recursion Pharmaceuticals, Inc.'s Class A Common Stock)

Key Players & Entities

  • RECURSION PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
  • Delaware (company) — state of incorporation for Recursion Pharmaceuticals, Inc.
  • Nasdaq Global Select Market (company) — exchange where Class A Common Stock is registered
  • 001-40323 (dollar_amount) — SEC File Number for Recursion Pharmaceuticals, Inc.
  • 41 S Rio Grande Street, Salt Lake City, UT 84101 (company) — principal executive offices address
  • January 8, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

  • The specific details of the Regulation FD disclosure will be released in accompanying exhibits. (Recursion Pharmaceuticals, Inc.) — high confidence, target: 2024-01-08

FAQ

What is the primary purpose of this 8-K filing by Recursion Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to disclose information under Regulation FD and to file financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated in 'Date of Report (Date of earliest event reported): January 8, 2024'.

What is the trading symbol and the exchange where Recursion Pharmaceuticals, Inc.'s Class A Common Stock is registered?

Recursion Pharmaceuticals, Inc.'s Class A Common Stock has the trading symbol RXRX and is registered on the Nasdaq Global Select Market, as detailed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the state of incorporation for Recursion Pharmaceuticals, Inc.?

Recursion Pharmaceuticals, Inc. is incorporated in Delaware, as specified in the filing under 'Delaware (State or other jurisdiction of incorporation)'.

What is the business address and phone number of Recursion Pharmaceuticals, Inc. as listed in the filing?

The business address of Recursion Pharmaceuticals, Inc. is 41 S Rio Grande Street, Salt Lake City, UT 84101, and their telephone number is (385) 269-0203, according to the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections.

Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-01-08 07:59:54

Key Financial Figures

  • $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 8, 2024, Recursion Pharmaceuticals, Inc. (the "Company") released an updated investor presentation. The investor presentation will be used at the JP Morgan Healthcare Conference and from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1. The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor presentation of Recursion Pharmaceuticals, Inc. dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on January 8, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Michael Secora Michael Secora Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.